Gene, Genome and Hormones - Clinical Research Informer

Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger

XTalks

FEBRUARY 21, 2025

In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety. This approach aims to combine TAS2R activation with enhanced incretin hormone modulation, potentially offering a more robust treatment for obesity and related conditions.

Genetics

Genetics Hormones Gene Expression Gene

In a gene tied to growth, scientists see glimmers of human history

Scienmag

SEPTEMBER 24, 2021

. — A new study delves into the evolution and function of the human growth hormone receptor gene, and asks what forces in humanity’s past may have driven changes to this vital piece of DNA. Genome assembly diagrams generated by the Integrative Genomics […].

Gene

Gene Scientist Genomics Genome

The FDA’s Guidance on Gene Edited Foods + What American Foods are Banned in Other Countries? – Xtalks Food Podcast Ep. 149

XTalks

MARCH 7, 2024

In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. Genome editing stands as a cutting-edge technique that ingeniously introduces new traits into plants.

Gene Editing

Gene Editing Gene Genome Genomics

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

International Women’s Day 2024: A Spotlight on 5 Women’s Health Webinars with Xtalks

XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Genetics

Genetics Hormones Genome Genomics

NICE backs two new breast cancer drugs for NHS use

pharmaphorum

JULY 14, 2022

Piqray (alpelisib) meanwhile is a once-daily, oral PI3K inhibitor that has been cleared for use in combination with hormonal therapy (fulvestrant) for hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer, that has progressed after endocrine and CDK4/6 inhibitor therapy.

Drugs

Drugs Hormones Genome Genomics

Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders

XTalks

MAY 23, 2024

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

Clinical Trials

Clinical Trials Clinical Trials Hormones Trials

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

APRIL 11, 2023

Another key focus at Bayer is on innovative precision oncology treatments, with an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread.

Research

Research Clinical Trials Clinical Trials Trials

From Gene to Protein: The Journey of Protein Expression Technology

Roots Analysis

SEPTEMBER 9, 2024

The main components of protein expression are a vector (plasmid) containing the gene of interest, and a host cell, for instance mammalian or prokaryotic cell. Protein expression process can be divided into following steps: Transcription: The DNA sequence of a gene is transcribed into mRNA.

Protein

Protein Gene Production DNA

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. degrader designed to inhibit the growth of tumour cells that have mutations in the PIK3CA gene. Lung cancer.

HR

HR Medicine Hormones Trials

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Immune-Mediated Pneumonitis.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Immune-Mediated Pneumonitis.

Trials

Trials Hormones Clinical Trials Clinical Trials

Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene

Gene Hormones DNA Medicine

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. Their tumor does not have an abnormal “EGFR” or “ALK” gene.

Medicine

Medicine Immune Response Protein Gene

Clinical Research Informer

Aardvark Therapeutics IPO Sets Sights on Satiating Hyperphagia and Extreme Hunger

In a gene tied to growth, scientists see glimmers of human history

Webinars

Trending Sources

The FDA’s Guidance on Gene Edited Foods + What American Foods are Banned in Other Countries? – Xtalks Food Podcast Ep. 149

Webinars

International Women’s Day 2024: A Spotlight on 5 Women’s Health Webinars with Xtalks

NICE backs two new breast cancer drugs for NHS use

Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

From Gene to Protein: The Journey of Protein Expression Technology

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Lynparza (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

Stay Connected